SEINE BIO · PEPTIDE PROFILE
Survodutide
Dual glucagon/GLP-1 agonist · global research
InvestigationalGet to know the name, understand the evidence, and prepare a more informed conversation.
What is Survodutide?
A glucagon/GLP-1 dual agonist studied in metabolic disease. Boehringer Ingelheim reports phase 3 results and a Chinese breakthrough-therapy designation. A designation is not marketing approval.
THE FULL READING GUIDE · UPDATED OCTOBER 7, 2026
Inside the science of Survodutide.
Educational purpose only. Not medical advice. Consult licensed provider. Obtain from authorized compounding pharmacies only.
Compounding is available only where lawful for the specific substance and patient. Approved finished medicines may also be dispensed by licensed non-compounding pharmacies; this disclaimer does not establish access to any investigational product.
Overview
Survodutide is an investigational dual glucagon/GLP-1 receptor agonist studied in obesity and metabolic liver disease. Those are related research interests, but a weight-loss trial and a biopsy-defined liver-disease trial answer different questions. Understanding that distinction helps keep promising headlines connected to the condition and population actually studied.
Community Use
PeptideDosages publishes a named vial protocol, and Peptidepedia presents a community-oriented overview. These are publisher descriptions, not authorization or prescribing guidance. Informal reports may borrow trial numbers without reproducing the trial’s eligibility, escalation, monitoring or adverse-event oversight.
Doses, Durations & Cycles
Informal biohacking protocols and published regimens. Attributed website reports for education, not medical recommendations. Multiple publications document circulation; they do not establish a safe dose or validate a cycle.
| Route / formulation | Dose / reported phases | Frequency | Duration / break | Notes and source |
|---|---|---|---|---|
| Subcutaneous | Initial 0.3 mg; separate assigned targets 0.6, 2.4, 3.6 or 4.8 mg | Weekly | 20 weeks escalation plus 26 weeks maintenance: 46 weeks Break: No biohacking break established by this study | Controlled phase 2 study Lancet Diabetes & Endocrinology 2024: dose-finding trial |
| Subcutaneous | Assigned targets 3.6 or 6 mg; initiation not established from the abstract reviewed | Weekly | 76 weeks Break: No biohacking break established by this study | Controlled phase 3 study NEJM 2026: SYNCHRONIZE-1 |
| See linked publisher; route not stated in audited excerpt | Community ranges: 0.3–0.6 mg weekly lower starts; 1.2–2.4 mg titration discussions; 2.4–4.8 mg higher trial-aligned reports. | Weekly amounts reported | No fixed total course stated Break: Not stated | Published informal biohacking claim PeptideReports.ca, Survodutide community protocol |
| See linked publisher; route not stated in audited excerpt | Reports 0.3–6 mg weekly range, 3.6 mg typical amount, and a website titration through 0.3, 0.6, 1.2, 2.4, 3.6, 4.8 and 6 mg. | Weekly amounts reported | No fixed total course stated Break: Not stated | Published informal biohacking claim Jacked Forums, Survodutide |
Important context: 0.3 mg is a verified phase 2 initiation dose; 2.4 mg is one study arm rather than an average. 4.8 mg is not an overall maximum because published phase 3 research includes 6.0 mg.
Additional sources: Developer-hosted phase 2 poster: starting dose. Consult the linked record for its exact formulation, population and methods.
Sources checked October 7, 2026. Educational listing does not establish prescribing approval or availability through Seine Bio.
The table separates study regimens from informal claims. The 2024 phase 2 study used assigned weekly arms over 46 weeks. SYNCHRONIZE-1 later studied weekly targets over 76 weeks. A higher arm in a later trial does not create a universal starting amount or personal maximum.
Research Findings
The phase 2 dose-finding work was followed by a phase 3 placebo-controlled obesity trial in adults without diabetes. Its design incorporated lifestyle counseling and treatment discontinuations. Separately, liver research uses disease-specific outcomes. Read the methods and population before translating either type of finding into a claim about general wellness.
U.S. Approval & Access
The cited phase 3 publication describes survodutide as investigational. A successful trial is not itself FDA approval. Neither a community protocol nor a clinician inquiry establishes an ordinary lawful supply pathway. Any proposed research access must be confirmed with the actual sponsor and study team.
What It Does in the Body
The molecule combines GLP-1 and glucagon receptor activity. This differs from tirzepatide’s GLP-1/GIP pairing and from triple agonists. Receptor labels alone cannot rank suitability. Reliable individual onset, peak benefit and persistence after stopping are not established for routine care; a trial’s duration is not a guaranteed duration of effect.
Benefits & Reported Experiences
At week 76, SYNCHRONIZE-1 reported mean weight changes of about 12–13% in its active groups versus 5.4% with placebo under its treatment-regimen analysis. Those are group results from a defined study, not expected personal outcomes or evidence that an online material reproduces the studied medicine.
Side Effects & Risks
Gastrointestinal symptoms were common in the phase 3 study. Tolerability and discontinuations affect practical outcomes as much as the highest headline percentage. The observed adverse-event profile belongs to the studied formulation and participants; it cannot establish the safety of unverified material or combined self-directed use.
Delivery Options
Published obesity studies used subcutaneous administration. That route is part of the clinical intervention. There is no basis here for substituting an oral preparation or another route. The article provides research context rather than injection technique, preparation instructions or a consumer treatment schedule.
Product Quality & Storage
Identity, formulation and lawful provenance matter alongside laboratory testing. A research-vial label does not demonstrate equivalence to the trial product. No verified patient-use storage specification is established here for community materials; an authorized program must provide its exact product’s storage, handling and monitoring requirements.
Combinations & Interactions
Survodutide already combines two receptor actions within one molecule. Adding a GLP-1 medicine, another metabolic agonist or an unapproved peptide is a separate intervention. Informal stacking discussions do not establish the safety of that combination, and this article does not offer a timing or combination protocol.
Talking With Your Provider
If your interest is weight care or liver health, start with the actual diagnosis and treatment goal. A qualified provider can compare established options and explain whether an appropriate research program exists. Studying a new molecule should not delay evaluation of diabetes, liver disease, nutrition or other conditions needing current care.
Educational purpose only. Not medical advice. Consult licensed provider. Obtain from authorized compounding pharmacies only.
Compounding is available only where lawful for the specific substance and patient. Approved finished medicines may also be dispensed by licensed non-compounding pharmacies; this disclaimer does not establish access to any investigational product.
Questions about what you read?
Explore the research library Create a free account
Educational information only. A free account lets you request review of your care goals. This profile does not establish availability, clinical suitability or access to the named compound.
Explore clinically appropriate options with a licensed provider. Inquiry does not guarantee a prescription, research-program acceptance or access to a particular substance.
Questions worth bringing to your appointment.
- Are there alternatives that address my goal?
- If treatment is appropriate, what monitoring and follow-up would I need?
- Could my health history or current medicines change the risks?
A clinician may recommend a different option—or no medication—after assessing your individual circumstances.
Saved discussion topics 0
Save topics you would like to discuss with your healthcare provider. Saving is an expression of interest, not a treatment request or medical recommendation.
Saved only in this browser, on this device—not in a patient account. Other people using this browser may see your list. Clear it when using a shared device. This list is not sent to our team.
Bring your curiosity. Start a conversation.
Create a free account to request review and manage purchases. Paid membership is optional. Clinical review and authorization still apply where required, and any separate service charges are shown before you agree to pay.
Create a free account ↗This educational information is free to read. Create a free account to request review of your care goals. Neither an account nor paid membership guarantees a prescription, access to the named compound or research enrollment.
Educational profile · U.S. context · October 7, 2026. This page does not provide personalized medical advice, dosing, or injection instructions.
Bring your saved topics to your care team.
Members can select up to five favorites and send a message for review. Your saved list stays in this browser until you choose what to submit.
Choose saved topics for review →